STAT June 21, 2024
Meghana Keshavan

Buenos dias! Writing from one of the more unique locations in my tenure as a Readout author…. Hola from a mercado in Mexico City. On tap today: Early studies show that checkpoint inhibitors may be more effective if combined with JAK inhibitors. Also, more promising anti-obesity results and perhaps a more potent PrEP for HIV.

Sarepta gene therapy approved for most Duchenne patients

The FDA yesterday dramatically expanded its approval for Elevidys, a gene therapy for Duchenne muscular dystrophy, authorizing access for nearly all patients with the fatal muscle-wasting disease.

It’s clear that the treatment, made by Sarepta Therapeutics, won’t be a panacea — “No one pretends this is a cure,” one patient’s mother told STAT’s Jason Mast — but...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Pharma / Biotech
Cancer Therapy and The Intestinal Microbiome
Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions
GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity
A New Target To Boost Cancer Immunotherapy: LAG-3
STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

Share This Article